#ESMO26 🧬 DEWI | Phase II
👥 43 pts | Localized dMMR/MSI-H GEA
💊 Dostarlimab → Watch & Wait if cCR
🎯 1-y cCR with organ preservation: 67.4% (29/43)
✅ No relapse or death among 29 W&W pts
🏥 Surgery: 14/43 (32.5%)
⚠️ Follow-up: 14.9 mo
💡 Promising organ-preserving strategy!
@OncoAlert @OncobitesTv
332 views · 2 likes · 4 reposts · 1 reply
Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study
https://esmocongress.esmo.org- Muzamil Arshad, MD/PhD@MuzamilArshad18
@DraMartinezLago @OncoAlert @myESMO @GrupoTTD Among non cCR could addition of RT prevent surgery in 1/3 who needed surgery?! 🤔 But also Niche studies with dual checkpoint had near 100% responses as I recall .. exciting to see various combo options for organ preservation … for other 95+% cases love IO+ ☢️ trials
Source: Nieves Martinez Lago MD PhD · x.com